How do renal artery stenosis and fibromuscular dysplasia differ in terms of epidemiology, pathophysiology, imaging appearance, and management?

Renal Artery Stenosis vs Fibromuscular Dysplasia: Key Differences

Fibromuscular dysplasia (FMD) is a specific non-atherosclerotic disease entity that causes renal artery stenosis (RAS), whereas renal artery stenosis is a broader term encompassing any narrowing of the renal arteries from multiple etiologies, with atherosclerosis accounting for approximately 90% of cases and FMD representing the second most common cause at approximately 10%. 1

Fundamental Relationship

• RAS is the anatomic finding (stenosis), while FMD is one of several disease processes that can cause it 1
• FMD is specifically defined as a non-atherosclerotic, non-inflammatory disease that most commonly affects the renal arteries 1
• Atherosclerotic RAS and FMD-related RAS represent distinct pathophysiologic entities requiring different management approaches 2, 3

Epidemiology

Atherosclerotic RAS

• Accounts for approximately 90% of all renovascular stenotic lesions 1
• Predominantly affects older patients (>55 years) with systemic atherosclerosis 4, 5
• More common in men and increases with age 6
• Associated with other atherosclerotic vascular disease (coronary, carotid, peripheral arteries) 1

Fibromuscular Dysplasia

• Represents the second most common cause of RAS at approximately 10% 7, 8
• Classic presentation: hypertension in young women (25-50 years old), with a female-to-male preponderance of 9:1 1, 4
• Can occur in both genders at any age 1
• Affects up to 4% of adults; more than half have renal artery involvement 4
• May involve multiple vascular territories (cervicocranial in one-third of cases) 4, 5

Pathophysiology

Atherosclerotic RAS

• Manifestation of systemic atherosclerosis involving lipid deposition, inflammation, and plaque formation 1
• Progressive disease associated with traditional cardiovascular risk factors (smoking, dyslipidemia, diabetes) 4, 2
• Part of generalized atherosclerotic burden 1

Fibromuscular Dysplasia

• Medial fibroplasia accounts for 80-85% of FMD cases, characterized by alternating areas of thinned media and thickened fibromuscular ridges containing collagen 1
• Considered a systemic disease with possible genetic etiology (though exact cause remains elusive) 2
• Risk factors include estrogen treatment and smoking 2
• Other histologic subtypes include perimedial fibroplasia (10-15%), medial hyperplasia (1-2%), intimal fibroplasia (<10%), and adventitial fibroplasia (<1%) 1

Anatomic Location

Atherosclerotic RAS

• Predominantly affects the aorto-ostial segment and proximal 1 cm of the main renal artery 1
• Represents intrinsic renal plaque extending to and contiguous with the aorta 1

Fibromuscular Dysplasia

• Characteristically involves the middle and distal two-thirds of the main renal artery 1
• May extend into renal artery branches 1
• Often involves both renal arteries bilaterally 1

Imaging Appearance

Atherosclerotic RAS

• Ostial or proximal focal stenosis on angiography 1
• Concentric smooth stenosis pattern 1
• Often calcified plaques visible on CT 7

Fibromuscular Dysplasia

• Pathognomonic "string of beads" appearance on angiography, where the diameter of the "beading" is larger than the normal arterial diameter (medial fibroplasia) 1
• Perimedial fibroplasia shows beading where "beads" are smaller than arterial diameter 1
• Mid-to-distal renal artery involvement 1

Diagnostic Approach

Initial Screening (Both Conditions)

• Duplex ultrasonography recommended as first-line screening (peak systolic velocity ≥200 cm/s, renal-aortic ratio >3.5) 1, 6
• CT angiography or MR angiography recommended when duplex is inconclusive or suspicious 1, 4, 1, 6
• Catheter angiography remains the gold standard when clinical suspicion is high and noninvasive tests are inconclusive 1

Clinical Clues for Atherosclerotic RAS

Investigation warranted with ≥2 of the following 4, 5:

• Sudden onset or worsening hypertension and age >55 years 4, 5
• Abdominal bruit 4, 5
• Hypertension resistant to 3 drugs 4, 5
• ≥30% increase in serum creatinine with ACE inhibitor/ARB use 4, 5
• Other atherosclerotic vascular disease, particularly with smoking or dyslipidemia 4, 5
• Recurrent pulmonary edema with hypertensive surges 4, 5

Clinical Clues for FMD

Investigation warranted with ≥1 of the following 4, 5:

• Significant unexplained asymmetry in kidney sizes (>1.5 cm) 4, 5
• Abdominal bruit without apparent atherosclerosis 4, 5
• FMD in another vascular territory 4, 5
• Family history of FMD 4, 5
• Age <30 years with new hypertension 4, 5

Additional Screening for FMD

• Screen for cervicocephalic lesions and intracranial aneurysm in confirmed renal FMD 5
• Screen other vascular beds if symptoms present 4, 5

Management Differences

Atherosclerotic RAS

Medical therapy is the primary treatment approach 5, 9, 6:

• Optimal medical therapy (OMT) with aggressive cardiovascular risk factor modification is recommended for all patients 9, 6, 2
• Antiplatelet therapy is reasonable 6
• ACE inhibitors/ARBs are effective for unilateral RAS but contraindicated in bilateral severe RAS or stenosis to a solitary kidney 9

Revascularization considerations 5, 9, 10:

• Renal artery stenting offers no benefit over optimal medical therapy alone for most patients 5
• Stenting may be considered (Class IIa-IIb) for specific high-risk features 5, 9, 6:
  • Uncontrolled hypertension resistant to maximally tolerated pharmacotherapy 5, 10
  • Progressive renal function loss 5, 10
  • Recurrent flash pulmonary edema 5, 9, 10
• Stenting is recommended over balloon angioplasty alone for ostial atherosclerotic lesions when revascularization is indicated 9, 10

Fibromuscular Dysplasia

Revascularization is the preferred treatment approach 5, 9, 10:

• Balloon angioplasty without stenting is recommended as first-line treatment 5, 9, 10
• Stenting should be avoided unless needed for periprocedural dissection 5, 11
• Stenting in FMD carries a high risk of late complications (57.9% stent-related complications including in-stent restenosis, under-expansion, and occlusion) 11
• Surgical revascularization should be considered for complex lesions, stenosis with complex aneurysm, or restenosis after 2 unsuccessful angioplasty attempts 5

Outcomes of angioplasty for FMD 12:

• Technical success rate: 94.3% 12
• Hypertension cure rate (BP <140/90 mmHg without medication): 18.1% using current definitions 12
• Overall improvement in hypertension: 80% 12
• Cure rates decline significantly with increasing patient age and duration of hypertension 12

Referral 5:

• Patients with confirmed renal FMD should be referred to a hypertension specialist 5

Critical Pitfalls

Common Diagnostic Errors

• Captopril renal scintigraphy is NOT recommended as a screening test for RAS 1
• Selective renal vein renin measurements and plasma renin activity are not useful screening tests 1
• In patients with chronic kidney disease (eGFR <60 mL/min/1.73 m²), captopril-enhanced radioisotope scanning is not recommended 4

Treatment Pitfalls

• Do not routinely stent atherosclerotic RAS—multiple RCTs (ASTRAL, CORAL) show no benefit over medical therapy for most patients 9, 6
• Avoid stenting in FMD except for procedural complications—high rates of stent-related complications including occlusion 5, 11
• Never use ACE inhibitors/ARBs in bilateral severe RAS or stenosis to a solitary kidney—risk of acute renal failure 1, 9

Age-Related Considerations

• Elderly patients with known FMD who develop recurrent renovascular hypertension may have developed new atherosclerotic RAS requiring repeat diagnostic evaluation 13
• This represents a distinct clinical scenario requiring recognition of both disease processes 13